Premium
Phosphorus Management in End‐Stage Renal Disease
Author(s) -
Finn William F.
Publication year - 2005
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/j.1525-139x.2005.18116.x
Subject(s) - hyperphosphatemia , medicine , lanthanum carbonate , phosphorus , phosphate , kidney disease , phosphate binder , dialysis , intensive care medicine , sevelamer , endocrinology , biochemistry , biology , materials science , metallurgy
Chronic kidney disease is an important public health problem, with an increasing number of patients worldwide. One important outcome of renal failure is disordered mineral metabolism, most notably involving calcium and phosphorus balance. Of importance is that increased serum phosphorus levels are associated with increased mortality rates. Despite dietary restrictions, patients receiving dialysis invariably experience hyperphosphatemia and require treatment with phosphate binders. Existing phosphate binders are effective in reducing serum phosphorus levels, but are associated with a number of important disadvantages. Lanthanum carbonate, a new noncalcium, nonaluminum phosphate binder, represents a promising treatment for hyperphosphatemia.